Chest:肺分配评分阈值优先考虑肺移植后的存活率

2019-01-19 xiangting MedSci原创

初始LAS≥70患者的LTx生存获益一致。该结果支持对LAS≥70患者进行供体肺分配的优先级平等化。

肺分配评分(LAS)优先考虑那些不移植存活率差且肺移植(LTx)有预期生存获益的LTx候选者。尽管LAS最高的患者等待时间最短,但该组的死亡率获益尚不清楚,这导致了对LAS不恰当地优先考虑重症候选者的批评。这项研究目标是确定一个阈值,高于该阈值后LAS升高不再预测生存获益的增加。

检索2005年5月至2016年12月器官共享登记联合网络中LAS≥30的首次成人LTx候选者。对等待移植到移植后期的生存率进行跟踪,并使用比例风险回归,与仍在等待移植患者的生存率进行比较。对LTx的生存获益建模为分段恒定的时间依赖性协变量,由候选者LAS调节。

在整个队列(N=21,157)中,LTx对365例初始LAS 70-79的患者具有特别保护性(与仍等待移植的患者比较,LTx后的死亡风险比[HR]=0.2; 95%置信区间[CI] ]:0.1,0.3)。然而,对于1,042例LAS更高的患者,LTx的生存获益并没有显著增加。囊性纤维化(CF)患者中,LAS约50以上LTx的生存获益保持不变。

初始LAS≥70患者的LTx生存获益一致。该结果支持对LAS≥70患者进行供体肺分配的优先级平等化。CF患者最高优先级的LAS阈值较低。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862937, encodeId=a499186293e24, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Sep 26 22:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929537, encodeId=2fa9192953e78, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jun 30 07:33:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051328, encodeId=e34f205132873, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 17 13:33:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553607, encodeId=0dae155360e10, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Mon Jan 21 00:33:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358610, encodeId=e61d35861062, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Jan 19 10:15:10 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862937, encodeId=a499186293e24, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Sep 26 22:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929537, encodeId=2fa9192953e78, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jun 30 07:33:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051328, encodeId=e34f205132873, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 17 13:33:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553607, encodeId=0dae155360e10, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Mon Jan 21 00:33:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358610, encodeId=e61d35861062, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Jan 19 10:15:10 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-06-30 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862937, encodeId=a499186293e24, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Sep 26 22:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929537, encodeId=2fa9192953e78, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jun 30 07:33:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051328, encodeId=e34f205132873, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 17 13:33:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553607, encodeId=0dae155360e10, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Mon Jan 21 00:33:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358610, encodeId=e61d35861062, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Jan 19 10:15:10 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862937, encodeId=a499186293e24, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Sep 26 22:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929537, encodeId=2fa9192953e78, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jun 30 07:33:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051328, encodeId=e34f205132873, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 17 13:33:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553607, encodeId=0dae155360e10, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Mon Jan 21 00:33:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358610, encodeId=e61d35861062, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Jan 19 10:15:10 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-21 qjddjq
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862937, encodeId=a499186293e24, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Sep 26 22:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929537, encodeId=2fa9192953e78, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jun 30 07:33:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051328, encodeId=e34f205132873, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 17 13:33:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553607, encodeId=0dae155360e10, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Mon Jan 21 00:33:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358610, encodeId=e61d35861062, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Jan 19 10:15:10 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 lietome24

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

相关资讯

NEJM:VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化

研究认为,VX-445-tezacaftor-ivacaftor三连疗法可显著改善Phe508del CFTR蛋白功能,改善Phe508del-MF或Phe508del-Phe508del突变型囊性纤维化患者呼吸功能

Thorax:曲霉菌与囊性纤维化患儿肺疾病进展

由此可见,在患有囊性纤维化的儿童中,5岁时阳性的曲霉BAL培养物与空气诱捕同时不伴有支气管扩张相关。然而,阳性曲霉BAL培养物与5岁时预测的FEV1%或5岁至14岁之间肺功能下降之间未观察到关联。

Nature:重磅!两篇论文共同揭示:新型肺细胞

8月1日,《Nature》连发两篇文章,同时揭示了一种新型肺细胞——“肺部离子细胞”(pulmonary ionocyte)。两个不同的研究团队利用单细胞RNA测序技术对人类以及小鼠的呼吸道细胞绘制了详细的分子图谱,从中发现了新的知识点。

FDA批准Vertex公司的Kalydeco药物用于治疗两岁以下的囊性纤维化儿童患者

Vertex Pharmaceuticals公司的囊性纤维化药物Kalydeco在美国的适应症进一步扩大,FDA已经批准将该药物用于治疗24个月以下的囊性纤维化(CF)儿童患者,这些患者体内都至少存在一个跨膜传导调节因子(CFTR)基因突变。

2018 ISPAD临床实践指南:儿童和青少年囊性纤维化相关性糖尿病的管理

2018年8月,国际儿童青少年糖尿病协会(ISPAD)发布了儿童和青少年囊性纤维化相关性糖尿病的管理指南,囊性纤维化是高加索人常见的致死性常染色体阴性遗传疾病,囊性纤维化相关性糖尿病是囊性纤维化患者最常见的共病,本文主要针对儿童和青少年囊性纤维化相关性糖尿病的管理提出指导建议。

NEJM:VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化

研究认为,VX-659-tezacaftor-ivacaftor三连疗法可显著改善Phe508del CFTR蛋白功能,改善Phe508del-MF或Phe508del-Phe508del突变型囊性纤维化患者呼吸功能